{
    "clinical_study": {
        "@rank": "111095", 
        "arm_group": [
            {
                "arm_group_label": "GS-5745", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive GS-5745 every 2 weeks for a total of 3 infusions."
            }, 
            {
                "arm_group_label": "Placebo to match GS-5745", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple\n      infusions of GS-5745 in participants with chronic obstructive pulmonary disease (COPD) as\n      assessed by adverse events (AEs) and laboratory abnormalities."
        }, 
        "brief_title": "Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Weight: \u2265 45 kg to < 120 kg at screening\n\n          -  Males or non-pregnant, non-lactating females\n\n          -  Male subjects and female subjects of childbearing potential who engage in\n             heterosexual intercourse must agree to use protocol specified method(s) of\n             contraception. Male subjects must refrain from sperm donation for 90 days post last\n             infusion of the study drug\n\n          -  Diagnosis of COPD per Global Initiative for Chronic Obstructive Lung Disease (GOLD)\n             guidelines for at least 6 months prior to screening and anticipated to remain on\n             stable therapy for the duration of the study\n\n          -  Post-bronchodilator forced expiratory volume in one second (FEV1) \u2265 40% predicted\n\n          -  No changes in COPD medications within 30 days prior to randomization\n\n          -  Hepatic panel [aspartate aminotransferase (AST), alanine aminotransferase (ALT),\n             total bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase (LDH)]\n             \u2264 2 times the upper limit of the normal range (ULN)\n\n          -  Serum creatinine \u2264 2.0\n\n          -  Hemoglobin \u2265 8.5 g/dL (both males and females)\n\n          -  Absolute neutrophil count (ANC) \u2265 1.5 x 10^9/L (1,500 mm^3)\n\n          -  Platelets \u2265 100 x 10^9/L\n\n        Exclusion Criteria:\n\n          -  Clinically significant active infection as judged by the investigator during\n             screening\n\n          -  Known history of HIV, hepatitis B or C during screening. Subjects who are hepatitis B\n             surface antigen positive, but who received a successful series of hepatitis B\n             vaccinations and never had the disease remain eligible\n\n          -  A positive QuantiFERON-TB GOLD test during screening\n\n          -  History of malignancy within the last 5 years except for patients who have been\n             treated locally for non-melanoma skin cancer or cervical carcinoma in situ\n\n          -  Any serious cardiac event such as myocardial infarction, unstable or life-threatening\n             arrhythmia, hospitalization for cardiac failure within 6 months prior to\n             randomization or any significant or new electrocardiogram (ECG) finding at Visit 1 as\n             judged by the Investigator\n\n          -  A hospitalization for a respiratory event such as, but not limited to, COPD,\n             pneumonia, bronchiolitis, within the previous 6 months prior to randomization\n\n          -  Chronic lung disease other than COPD such as: asthma, cystic fibrosis or fibrotic\n             disease, \u03b1-1-antitrypsin deficiency, interstitial lung disease, pulmonary\n             thromboembolic disease, or bronchiectasis\n\n          -  Chronic use of systemic corticosteroids and/or treatment with systemic\n             corticosteroids for an acute exacerbation of COPD (AECOPD) event, or other medical\n             condition not requiring hospitalization, within 90 days of randomization.\n\n          -  Treatment with antibiotics for an AECOPD event, or other medical condition not\n             requiring hospitalization within 90 days of randomization, or any minor medical event\n             not requiring hospitalization within 14 days of randomization.\n\n          -  Treatment with any marketed or investigational biologic within 5 half-lives of the\n             molecule or if unknown within 90 days of screening\n\n          -  Subjects currently on nonbiologic immune modulator medications such as: azathioprine,\n             cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate mofetil,\n             sulfasalazine, tofacitinib, within 90 days of randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077465", 
            "org_study_id": "GS-US-368-1212"
        }, 
        "intervention": [
            {
                "arm_group_label": "GS-5745", 
                "description": "400 mg GS-5745 administered intravenously", 
                "intervention_name": "GS-5745", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to match GS-5745", 
                "description": "Placebo to match GS-5745 administered intravenously", 
                "intervention_name": "Placebo to match GS-5745", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "COPD, chronic obstructive pulmonary disease; Phase 1b, Safety, Pharmacokinetics", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Advanced Pharma CR, LLC"
                }, 
                "investigator": {
                    "last_name": "Gilbert Weiner, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33169"
                    }, 
                    "name": "Elite Research Institute"
                }, 
                "investigator": {
                    "last_name": "Juan C Rondon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Compass Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Kevin Radbill, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14203"
                    }, 
                    "name": "University at Buffalo CTRC"
                }, 
                "investigator": {
                    "last_name": "Manoj Mammen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "Volunteer Research Group"
                }, 
                "investigator": {
                    "last_name": "William Smith, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease", 
        "overall_contact": {
            "email": "sap@gilead.com", 
            "last_name": "Sophe Ap", 
            "phone": "206.832.2098"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "David Gossage, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This composite endpoint will measure the safety and tolerability profile of GS-5745.", 
            "measure": "Incidence of adverse events, change from screening in laboratory tests and vital signs, and development of immunogenicity after dosing", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Day 29 plus 30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077465"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC represents the total amount of drug absorbed by the body by comparing plasma concentration over time\nCmax is defined as the maximum concentration of drug", 
                "measure": "PK parameters of GS-5745 as measured by AUC and Cmax", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 29"
            }, 
            {
                "description": "Tmax is defined as the time of Cmax\nClast is defined as the last observable concentration of drug\nTlast is defined as the time of Clast\nCtau is defined as the observed drug concentration at the end of the dosing interval\n\u03bbz is defined as the terminal elimination rate constant\nCL is defined as systemic clearance following intravenous (IV) administration\nVz is defined as apparent volume of distribution following IV administration", 
                "measure": "PK parameters of GS-5745 as measured by Tmax, Clast, Tlast, Ctau, \u03bbz, CL, and Vz", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 29"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}